TEM at a glance
Tempus AI Inc (TEM, SEC CIK 1717115) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Tempus AI Inc (TEM) reported revenue of $1.3 billion (up 83.4% from FY2024) and a net loss of $245.0 million. Diluted EPS was -$1.41.
- As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Tempus AI Inc (TEM) shares worth $4.5 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Polovin Andrew on November 17, 2026 of 581 shares at $64.02 per share.
- In the last 90 days, TEM insiders reported 0 open-market purchases ($0) and 106 open-market sales ($76.8M) on Form 4, a net sale of $76.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $1.3B
- +83.4% vs prior year
- Insiders · 90 days
- 0 buys · 106 sells
- Net −$76.8M
- 13F holders
- 35 funds
- $4.5B · −1 vs prior quarter
- Latest 8-K
- Nov 18, 2026
- Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New acquisition risk: Proposed Personalis deal may terminate if not completed by April 20, 2027, potentially triggering a $76.8 million fee
- Regulatory risk: Acquisition requires Personalis stockholder approval, regulatory clearances, and Nasdaq listing approval
- Operational risk: Integration may disrupt operations through employee, client, vendor, and service-provider losses
- Financial risk: Convertible Notes total $1.21 billion, with cash conversion potentially reducing liquidity
- Market risk: Failed acquisition could negatively affect Class A share price and results of operations
Management Discussion & Analysis
- Quarterly revenue $411.5M, up $77.3M from $334.2M YoY
- Diagnostics revenue $303.5M vs $252.9M, strongest segment, driven by oncology testing
- Data and applications revenue $108.1M vs $81.3M, increased Insights and Next demand
- Net loss $14.9M vs $80.0M, adjusted EBITDA $25.6M vs $1.5M
- Cash, equivalents and restricted cash $595.2M; operating cash use $71.6M, 2032 Notes proceeds $443.1M
- Near-term losses expected, with higher expenses for offerings, sales expansion and marketing; tariffs may raise technology costs
AI summary of the TEM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- AstraZeneca committed $200 million through 2031, providing Tempus visibility into a major multi-year revenue stream
- Annual target spend $40 million across existing and future Tempus products and services
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release issued November 2, 2026, with detailed results in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Supplemental financial information released for quarter ended September 30, 2026
- CEO and CFO letter posted alongside quarterly materials
Item EX-99.1: Item EX-99.1
- Q3 revenue $411.5M, up 23%, led by Oncology volume growth of 32% and Data & Applications growth of 33%
- Gross profit $266.7M, up 27%, with gross margin expanding to 64.8% from 62.8%
Item 8.01: Other Events
- $192.5M aggregate cash payments over approximately five years, creating significant contracted data and services revenue
- BMS oncology agreement: $137.5M through December 31, 2031, with quarterly invoicing and substantial termination fee
AI summaries of TEM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TEM
Don't miss the next TEM filing
- Alerts as it files. A push when TEM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TEM, by share count.
- Ask anything. An AI agent that reads every TEM filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Polovin Andrew | Sell | Nov 17, 2026 | 581 | $64.02 |
| Fukushima Ryan | Sell | Nov 17, 2026 | 890 | $64.02 |
| Polovin Andrew | Sell | Nov 17, 2026 | 4,020 | $63.23 |
| Rogers James William | Sell | Nov 17, 2026 | 4,240 | $63.23 |
| Fukushima Ryan | Sell | Nov 17, 2026 | 3,223 | $62.33 |
| Fukushima Ryan | Sell | Nov 17, 2026 | 6,134 | $63.23 |
| Rogers James William | Sell | Nov 17, 2026 | 614 | $64.02 |
| Polovin Andrew | Sell | Nov 17, 2026 | 2,103 | $62.33 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $693.4M | $1.3B |
| Operating Income | - | -$691.1M | -$252.9M |
| Net Income | -$214.1M | -$705.8M | -$245.0M |
| Op. Margin | - | -99.7% | -19.9% |
| Net Margin | - | -101.8% | -19.3% |
| Balance Sheet | |||
| Total Assets | $564.1M | $926.1M | $2.3B |
| Equity | - | $56.3M | $491.3M |
| ROE | - | -1252.8% | -49.9% |
| Per Share | |||
| EPS | $-4.20 | $-6.23 | $-1.41 |
| Cash Flow | |||
| Operating CF | - | -$189.0M | -$218.1M |
| CapEx | $34.6M | $22.1M | $21.0M |
Source: XBRL data in Tempus AI Inc (TEM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TEM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 35 | $4.52B |
| Q2 2026 | 36 | $3.17B |
| Q1 2026 | 34 | $2.11B |
| Q4 2025 | 32 | $2.91B |
| Q3 2025 | 34 | $4.70B |
| Q2 2025 | 36 | $2.83B |
| Q1 2025 | 23 | $1.35B |
| Q4 2024 | 15 | $374.1M |
- AQR Capital Management+1.60M (+2295%)
- BlackRock+1.33M (+16%)
- T. Rowe Price Group+844.0K (+793%)
- Invesco Ltd+819.9K (+408%)
- Two Sigma Investments+771.6K (+1208%)
- Goldman Sachs Group−2.83M (-75%)
- Morgan Stanley−1.57M (-43%)
- Bank of America Corp−1.16M (-61%)
- ARK Investment Management−665.1K (-7%)
- Citadel Advisors LLC−450.4K (-18%)
- D.E. Shaw & Co+1.77M
- Citizens Financial Group+4.0K
- Truist Financial+2.7K
- Millennium Management−146.1K
- FMR LLC (Fidelity)−71.3K
- Equitable Holdings Inc−7.9K
- StoneX Group Inc.−5.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 245 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TEM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 4 | Nov 4, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 10-Q | Nov 2, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 29, 2026 | - | - | - |
| 8-K | Oct 23, 2026 | - | Analysis | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
Related Information Technology companies
- APP · AppLovinServices-Computer Programming, Data Processing, Etc.
- BLND · Blend Labs, Inc.Services-Computer Programming, Data Processing, Etc.
- BMBL · Bumble Inc.Services-Computer Programming, Data Processing, Etc.
- CEVA · CEVA INCServices-Computer Programming, Data Processing, Etc.
- DOCN · DigitalOcean Holdings, Inc.Services-Computer Programming, Data Processing, Etc.
- EVER · EverQuote, Inc.Services-Computer Programming, Data Processing, Etc.
- GDS · GDS Holdings LtdServices-Computer Programming, Data Processing, Etc.
- GRND · Grindr Inc.Services-Computer Programming, Data Processing, Etc.
TEM SEC filings: frequently asked questions
Are TEM insiders buying or selling?
In the last 90 days, Tempus AI Inc (TEM) officers, directors and 10% owners reported no open-market purchases and 106 open-market sales worth $76.8 million by 9 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TEM stock?
As of September 30, 2026, the largest Tempus AI Inc (TEM) holders among the 13F filers tracked by SignalX were BlackRock ($788.3 million), ARK Investment Management ($766.4 million), JPMorgan Chase & Co ($440.4 million), Vanguard Capital Management LLC ($417.2 million), Vanguard Portfolio Management LLC ($413.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TEM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Tempus AI Inc (TEM) reported revenue of $1.3 billion (up 83.4% from FY2024) and a net loss of $245.0 million. Diluted EPS was -$1.41. The figures come from the XBRL data in the 10-K.
What did TEM report in its latest 8-K?
Tempus AI Inc (TEM) filed an 8-K on November 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). AstraZeneca committed $200 million through 2031, providing Tempus visibility into a major multi-year revenue stream.
What are the latest TEM SEC filings?
Tempus AI Inc (TEM) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 19, 2026.
What is TEM's SEC CIK number?
Tempus AI Inc (TEM)'s SEC Central Index Key (CIK) is 1717115. EDGAR lists every TEM filing under that number.
Ask anything about TEM
The research agent reads TEM's filings, financials, insider trades and 13F holders, then answers with sources.